From professional translators, enterprises, web pages and freely available translation repositories.
adenocarcinoma
adenokartsinoom
Last Update: 2017-04-26
Usage Frequency: 8
Quality:
non-adenocarcinoma
mitte-adenokartsinoom
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
gastric adenocarcinoma
mao adenokartsinoom
Last Update: 2017-04-26
Usage Frequency: 7
Quality:
adenocarcinoma (n = 847)
adenokartsinoom (n = 847)
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
non-adenocarcinoma female
adenokartsinoom mitteadenokartsinoom naine
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
dose adjustments during treatment of pancreatic adenocarcinoma
annuse kohandamine pankrease adenokartsinoomi ravi käigus
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
the vast majority of patients had adenocarcinoma (92.1%).
valdaval enamikul esines adenokartsinoom (92,1%).
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
efficacy of docetaxel in the treatment of patients with gastric adenocarcinoma
dotsetakseeli efektiivsus mao adenokartsinoomi ravis
Last Update: 2017-04-26
Usage Frequency: 7
Quality:
table 1: dose level reductions for patients with pancreatic adenocarcinoma
tabel 1: annuse taseme vähendamine pankrease adenokartsinoomiga patsientidel
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
gastric cancer and gastro-oesophageal junction (gej) adenocarcinoma
maovähk või gastroösofageaal-liidese adenokartsinoom
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
(5) progression of pre-existing pancreatic adenocarcinoma with kras mutation.
(5) olemasoleva kras mutatsiooniga pankrease adenokartsinoomi progresseerumine.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
chronic myelomonocytic leukaemia(2)(4), pancreatic adenocarcinoma(5)
krooniline müelomonotsütaarne leukeemia(2)(4), pankrease adenokartsinoom(5)
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
in metastatic adenocarcinoma of the pancreas, abraxane was shown to improve overall survival.
pankrease metastaatilise adenokartsinoomiga patsientidel suurendas abraxane üldist elulemust.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
29 adenocarcinoma of the gastroesophageal junction, who had not received prior chemotherapy for metastatic disease.
dotsetakseeli efektiivsust ja ohutust metastaatilise mao adenokartsinoomi, sh gastroösofageaalliidese adenokartsinoomi ravis patsientidel, kes ei olnud varem saanud kemoteraapiat metastaatilise haiguse raviks, hinnati paljukeskuselises avatud randomiseeritud uuringus.
Last Update: 2011-10-23
Usage Frequency: 1
Quality:
Warning: This alignment may be wrong.
Please delete it you feel so.
docetaxel 75 mg/m² in combination with cisplatin and 5-fluorouracil for gastric adenocarcinoma cancer
dotsetakseel 75 mg/m2, kombinatsioonis tsisplatiini ja 5-fluorouratsiiliga mao adenokartsinoomi raviks
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
20 taxotere 75 mg/ m² in combination with cisplatin and 5-fluorouracil for gastric adenocarcinoma cancer
20 taxotere 75 mg/ m2 kombinatsioonis tsisplatiini ja 5– fluorouratsiiliga mao adenokartsinoomi raviks:
Last Update: 2012-04-11
Usage Frequency: 4
Quality:
20 docetaxel winthrop 75 mg/ m² in combination with cisplatin and 5-fluorouracil for gastric adenocarcinoma cancer
20 docetaxel winthrop 75 mg/ m2 kombinatsioonis tsisplatiini ja 5– fluorouratsiiliga mao adenokartsinoomi raviks:
Last Update: 2012-04-11
Usage Frequency: 4
Quality:
5.8 % of the adenocarcinoma patients entered the study with locally recurrent disease stage as had been evaluated at baseline.
5,8% adenokartsinoomiga patsientidest kaasati uuringusse uuringu alguses määratud paikselt retsidiveerunud haiguse staadiumis.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
description of selected adverse reactions in gastric adenocarcinoma cancer for docetaxel 75 mg/m2 in combination with cisplatin and 5-fluorouracil
kõrvaltoimete valikuline kirjeldus mao adenokartsinoomi kombinatsioonravi korral dotsetakseeliga annuses 75 mg/ m² ning tsisplatiini ja 5-fluorouratsiiliga
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
diarrhoea occurred in 43.4 % (≥ grade 3: 6.3 %) of adenocarcinoma patients in the nintedanib arm.
kõhulahtisus esines nintedaniibi rühmas 43,4% (≥ 3. astme kõhulahtisust 6,3%) adenokartsinoomiga patsientidest.
Last Update: 2017-04-26
Usage Frequency: 1
Quality: